((Sara M. Tinsley, Ph.D., ARNP, AOCN))
It's important that patients are deemed clinically stable in order to use an IPOP approach.
A patient’s age should be considered, but age alone should not determine the treatment approach.
A patient’s proximity and their ability to get to an infusion center quickly are important.
The facility needs to have ample infusion chairs and availability to accommodate patients for a number of hours.
In addition to the patient coming in on Days 1, 3, and 5 for the 90-minute VYXEOS infusion during their first induction cycle, they typically will need to be at the outpatient clinic every day for a physical exam and blood transfusions, if needed.
During the exam, medications are reviewed and blood work is assessed to determine if platelet or red blood cell transfusions are needed.
The patient is checked for fever and asked about any new symptoms.
It is important to explain to the patient and caregiver that outpatient treatment likely means a half-day at the infusion center for blood collection, labs, and lab results.
VYXEOS is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t‑AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
IMPORTANT SAFETY INFORMATION